Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07604974 | A Study to Assess the Safety, Tolerability and Efficacy of ION775 | PHASE2 | RECRUITING | 72 | — | — | May 1, 2026 | Mar 1, 2028 | Jun 1, 2026 | 8 | United States |
| Arm | Type | Description |
|---|---|---|
| ION775: Cohot A | EXPERIMENTAL | Participants will be randomized to receive ION775 by subcutaneous (SC) injection. |
| ION775: Cohot B | EXPERIMENTAL | Participants will be randomized to receive ION775 by SC injection. |
| ION775: Cohot C | EXPERIMENTAL | Participants will be randomized to receive ION775 by SC injection. |
| Name | Type | Description |
|---|---|---|
| ION775 | DRUG | ION775 will be administered by SC injection. |
Key Inclusion Criteria: 1. Adult males and females with HTG (fasting TG more than or equal to (≥) 350 milligrams per deciliter (mg/dL) \[3.95 millimoles per liter (mmol/L)\] or with sHTG (fasting TG ≥ 500 mg/dL \[5.65 mmol/L\]). 2. Participants should be on standard of care lipid-lowering medicatio...